Current JAK inhibitor clinical trials for patients with an MPN
| . | JAK inhibitor [target(s)] . | Second agent . | Class second agent . | Disease . | Trial number (www.ClinicalTrials.gov) . |
|---|---|---|---|---|---|
| Single-agent trials | Pacritinib (JAK2, FLT3) | N/A | N/A | MF | NCT01773187 |
| Momelotinib (JAK1, JAK2) | N/A | N/A | MF, PV, ET | NCT01969838 (MF) | |
| NCT01998828 (PV and ET) | |||||
| NS-018 (JAK2) | N/A | N/A | MF | NCT01423851 | |
| INCB-039110 (JAK1) | N/A | N/A | MF | NCT01633372 | |
| Ruxolitinib combination trials | Ruxolitinib | Danazol | Androgen | MF | NCT01732445 |
| Ruxolitinib | Pomalidomide | IMID | MF | NCT01644110 | |
| Ruxolitinib | Lenalidomide | IMID | MF | NCT01375140 | |
| Ruxolitinib | Azacitidine | Hypomethylation | MF | NCT01787487 | |
| Ruxolitinib | Panobinostat | HDAC inhibitor | MF | NCT01693601 (US) | |
| NCT01433445 (UK) | |||||
| Ruxolitinib | GS-6624 | Antifibrosing | MF | NCT01369498 | |
| Ruxolitinib | PRM-151 | Antifibrosing | MF | NCT01981850 | |
| Ruxolitinib | BKM-120 | PI3-kinase inhibitor | MF | NCT01730248 | |
| Ruxolitinib | LDE-225 | Hedgehog inhibitor | MF | NCT01787552 | |
| Ruxolitinib (MPD-RC trial) | Allo-SCT | N/A | MF | NCT01790295 | |
| Ruxolitinib (GOELAMS trial, France) | Allo-SCT | N/A | MF | NCT01795677 |
| . | JAK inhibitor [target(s)] . | Second agent . | Class second agent . | Disease . | Trial number (www.ClinicalTrials.gov) . |
|---|---|---|---|---|---|
| Single-agent trials | Pacritinib (JAK2, FLT3) | N/A | N/A | MF | NCT01773187 |
| Momelotinib (JAK1, JAK2) | N/A | N/A | MF, PV, ET | NCT01969838 (MF) | |
| NCT01998828 (PV and ET) | |||||
| NS-018 (JAK2) | N/A | N/A | MF | NCT01423851 | |
| INCB-039110 (JAK1) | N/A | N/A | MF | NCT01633372 | |
| Ruxolitinib combination trials | Ruxolitinib | Danazol | Androgen | MF | NCT01732445 |
| Ruxolitinib | Pomalidomide | IMID | MF | NCT01644110 | |
| Ruxolitinib | Lenalidomide | IMID | MF | NCT01375140 | |
| Ruxolitinib | Azacitidine | Hypomethylation | MF | NCT01787487 | |
| Ruxolitinib | Panobinostat | HDAC inhibitor | MF | NCT01693601 (US) | |
| NCT01433445 (UK) | |||||
| Ruxolitinib | GS-6624 | Antifibrosing | MF | NCT01369498 | |
| Ruxolitinib | PRM-151 | Antifibrosing | MF | NCT01981850 | |
| Ruxolitinib | BKM-120 | PI3-kinase inhibitor | MF | NCT01730248 | |
| Ruxolitinib | LDE-225 | Hedgehog inhibitor | MF | NCT01787552 | |
| Ruxolitinib (MPD-RC trial) | Allo-SCT | N/A | MF | NCT01790295 | |
| Ruxolitinib (GOELAMS trial, France) | Allo-SCT | N/A | MF | NCT01795677 |
IMID indicates immunomodulatory drugs; N/A, not applicable.